Skip to main content

Fco. Xavier De la Cruz Montserrat

Our main research aims at understanding the molecular basis of hereditary disease, integrating two complementary aspects: the molecular impact of causative variants and how genetic background regulates the propagation of this impact. At a technical level, to reach our objective, we integrate the results of the most advanced genomic experiments (single-cell, Hi-C, etc.) using state-of-the-art machine learning tools. To enhance the biomedical reach of our research, we work in collaboration with clinical groups from different hospitals. As a result of these efforts, we have recently made significant advances in understanding the functional effect of BRCA1/2 protein variants underlying hereditary breast and ovarian cancers. Finally, mention that we are also devoting an important part of our efforts to the fundamental study of epigenetic processes, to reach a full picture of which phenomena contribute to the generation of phenotype and, more precisely, of clinical phenotype.

Institutions of which they are part

Head of group
Clinical and Translational Bioinformatics
Vall Hebron Institut de Recerca

Fco. Xavier De la Cruz Montserrat

Institutions of which they are part

Head of group
Clinical and Translational Bioinformatics
Vall Hebron Institut de Recerca

Our main research aims at understanding the molecular basis of hereditary disease, integrating two complementary aspects: the molecular impact of causative variants and how genetic background regulates the propagation of this impact. At a technical level, to reach our objective, we integrate the results of the most advanced genomic experiments (single-cell, Hi-C, etc.) using state-of-the-art machine learning tools. To enhance the biomedical reach of our research, we work in collaboration with clinical groups from different hospitals. As a result of these efforts, we have recently made significant advances in understanding the functional effect of BRCA1/2 protein variants underlying hereditary breast and ovarian cancers. Finally, mention that we are also devoting an important part of our efforts to the fundamental study of epigenetic processes, to reach a full picture of which phenomena contribute to the generation of phenotype and, more precisely, of clinical phenotype.

INTERESTS
My interests are devoted to studying the impact of pathogenic mutations and transform the
results into clinically useful Artificial Intelligence (AI) models.

HIGHLIGHTS
We ranked second in the groups' classification at the international challenge for in silico methods, CAGI 5 (inherited breast/ovarian cancers section). We won the Best Poster Prize of the Editor of 'Science' in HGM 2018 (Japan). In 2015, we participated in the identification of the glioblastoma signature in cerebro-spinal fluid (De Mattos-Arruda et al., Nature Communications, 6:8839), a project that won the Prize "La Vanguardia de la Ciencia".

EARLY CAREER
.- Ph.D. Thesis
Thesis (1990-1993, UPC, Barcelona). I worked in a relationship between atomic areas
and free energies (de la Cruz et al., J.Mol.Graphics, 10:96, 1992). During a stay in the lab of
van Gunsteren (ETH-Z, Zürich), I shifted toward the study of the structure/function relationship (de la Cruz et al., J. Mol. Biol., 236:1186, 1994).
Fellowships: FPI Generalitat (1990-93, UPC); EMBO Short Term (1992, ETH-Z).

.- Post-doctoral stays (1993-2000)
Two post-doctoral stays: NIH, USA (4 years) and UCL-EBI, UK (3 years). In these stays, I increased my background on structure/function relationship (analog structure comparisons: de la Cruz & Lee, Protein Sci., 5:857, 1996; beta-turn prediction: de la Cruz et al., PNAS, 99:11157, 2002).
Fellowships: Fogarty Fellowship (1993-97, USA); MEC fellowship for doctors (1997); Human
Frontier Science Program (HFSP) (1997-99, UK).

PRESENT (2000-**) ICREA Research Professor
Our research aims at understanding/predicting the impact of pathogenic of variants using AI. Our initial approach (Ferrer-Costa et al., J. Mol. Biol. 2002; Proteins, 2004; Bioinformatics, 2005) has been broadly followed (>920 citations). After joining VHIR (2012) we have designed a novel approach to pathogenicity prediction (Riera et al., Hum. Mut., 2016). This crystallized in the model for BRCA1/2 variants (Padilla et al., Hum. Mut., 2019) that we presented at the international CAGI contest (see above). We have further tested this result to extend it to the clinical genome (Özkan et al., IJMS, 2020). Our expertise is reflected in our collaborations (see below for our collaboration with E. Bhoj at the Children’s Hospital of Philadelphia).

We have worked also in the epigenetic regulation of gene expression, where I would like to
single out two of our publications (co-corresponding author in both), one in PNAS (Pappa et
al., 2019) about DNA damage prevention and the second in Development (Estarás et al., 2012)
on the regulation of neural development by JMJD3.
Contracts: Reincorporación MEC (2000-2001), ICREA Research Professor (2001-nowadays).

-Skills. We have a deep understanding of the molecular basis of hereditary diseases.
Technically, we are proficient in the development of AI tools for pathogenicity prediction. We
are also proficient in the structural/functional characterization of protein mutations using
computational/bioinformatics approaches.

-International collaborations. We have an ongoing collaboration with E. Bhoj (Children’s
Hospital of Philadelphia) for the clinical characterization of histone H3.3 variants. This work
has lead to a high-impact publication (Bryant et al., Science Advances, 2020) in which we
leadered the in silico analyses of the whole consortium (137 authors) in a study resulting in the discovery of a new neurodegenerative disorder.

-Training researchers. I have supervised 11 Ph.D. theses. The majority of the students work
in bioinformatics/computation.

Projects

Grup de Bioinformàtica Translacional en Neurociències

IP: Fco. Xavier De la Cruz Montserrat
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109440
Reference: CD08/00241
Duration: 01/08/2009 - 31/07/2013

Related news

The Clinical and Translational Bioinformatics Group at VHIR has been responsible for the computational analysis of two international genetic studies led by the Children's Hospital of Philadelphia.

The Clinical and Translational Bioinformatics group is launching the project to use cutting-edge artificial intelligence in the identification of pathogenic variants.

Related professionals

Lluis Armadans Gil

Lluis Armadans Gil

Main researcher
Epidemiology and Public Health
Read more
Lastiri González, Ernesto Alejand

Lastiri González, Ernesto Alejand

Predoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
Esteve Trias Adroher

Esteve Trias Adroher

Senior researcher
Donation and transplantation of organs, tissues and cells
Read more
Torres Barbosa, Asbleidy Carolina

Torres Barbosa, Asbleidy Carolina

Research technician
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.